Biology Atlas

Map / Drugs

drug · intermediate · partly written

Axicabtagene ciloleucel (Yescarta)

Axicabtagene ciloleucel is an autologous CD19-directed CAR T cell product approved for refractory large B-cell lymphoma.

Also called: axi-cel, Yescarta

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

What it is in one breath

A CD19 CAR T product for adults with refractory large B-cell lymphoma. In the ZUMA-1 trial 82% of 101 treated patients responded and 54% had a complete response, with serious cytokine release and neurologic events in a minority. 1

Reported, not yet replicated

The decisive trial: ZUMA-1 more

ZUMA-1 was a multicentre phase 2 trial in 111 patients with refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma. The product was manufactured for 110 and administered to 101 after low-dose cyclophosphamide plus fludarabine. Response was 82% and complete response 54%. At median follow-up of 15.4 months, 42% continued to respond; overall survival at 18 months was 52%. Higher CAR T levels in blood were associated with response.

The FDA review reports lower figures from the independent review committee than the investigator-assessed ones above: 72% objective and 51% complete. Trials were single arm; FDA judged historical comparison adequate (SCHOLAR-1, as quoted in the review). 12

Reported, not yet replicated

Compared with tisagenlecleucel deep

Both are autologous CD19 products that carry a CD3 zeta signal. Axi-cel uses a gamma-retroviral vector and a CD28 costimulatory domain; tisagenlecleucel uses a lentiviral vector and 4-1BB, which FDA describes as important for persistence. The trials are in different diseases and age groups, so their rates are not comparable. 23

Reported, not yet replicated

Modality

CAR T cell therapy

Targets

Pathways

Indications

Identifiers

Nct zuma1

NCT02348216

Mechanism

The patient's T cells are engineered with a gamma-retroviral vector to carry a CD19-binding mouse-derived antibody fragment with CD3 zeta and a CD28 costimulatory domain, expanded, and infused after cyclophosphamide plus fludarabine conditioning. Binding CD19 activates the cell to kill and divide. 2

Reported, not yet replicated

Delivery route

Must survive

Manufacture: in ZUMA-1 the product was made for 110 of 111 enrolled patients and given to 101. The median time from collection to delivered product was 17 days (range 14 to 51) in the FDA review. The cells are the patient's own, so they are not rejected as a graft. 12

Reported, not yet replicated

Side effects

Cytokine release syndrome and neurologic events

Grade 3 or higher CRS in 13% and neurologic events in 28% of patients in ZUMA-1; three patients died during treatment. The FDA review states that fatal and life-threatening events occurred and that serious or fatal cerebral edema was reported in a safety update. 12

Reported, not yet replicated

Blood count falls

Grade 3 or higher neutropenia 78%, anemia 43%, thrombocytopenia 38%. 1

Reported, not yet replicated

Verdict

Outcome

worked

Why

In ZUMA-1 (phase 2, single arm, 111 enrolled, 101 treated) the objective response rate was 82% and complete response 54%; at a median 15.4 months of follow-up 42% still had a response; survival at 18 months was 52%. The independent committee gave lower figures (72% objective, 51% complete) than investigators. FDA approved it on 18 Oct 2017. 12

Reported, not yet replicated

Teach this

In one sentence

Axi-cel is the patient's own T cells fitted with a CD19-seeking receptor with a CD28 signal, used in refractory large B-cell lymphoma. 1

Reported, not yet replicated

The common wrong idea

The headline 82% is how many patients the drug cured.

It is an objective response rate in a single-arm trial, which counts partial responses, and the independent committee's figures were lower than the investigators'.

The one citation to hand over: 1

Still open here

Not yet written: Assays used, Off targets.

Linked from

Sources

  1. Neelapu, S. S., et al.. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine (2017). paper; opened 2026-11-17 all records citing this
  2. FDA Summary Basis for Regulatory Action: Yescarta (axicabtagene ciloleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. Maude, S. L., et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine (2018). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Year
2017
Regulatory status
approved
Status
partly written
Last updated
2026-11-17
Record
content/drugs/axicabtagene-ciloleucel.json